The third quarter saw a raft of first-in-class approvals, including the first RNA interference (RNAi) drug, the first nanobody, and a novel immunotoxin combining a CD22 Fv antibody fragment and an exotoxin. RNAi, antisense and small molecules achieved clinical milestones in hereditary transthyretin amyloidosis for both neuropathy and cardiomyopathy. Disappointing trial data presented a major setback for indoleamine 2,3-dioxygenase inhibitors in immuno-oncology.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Drug pipeline 3Q18. Nat Biotechnol 36, 1132 (2018). https://doi.org/10.1038/nbt.4310
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.4310